GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (STU:CT9) » Definitions » Common Stock

Cardiol Therapeutics (STU:CT9) Common Stock : €120.21 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cardiol Therapeutics Common Stock?

Cardiol Therapeutics's quarterly common stock declined from Jun. 2024 (€103.27 Mil) to Sep. 2024 (€102.85 Mil) but then increased from Sep. 2024 (€102.85 Mil) to Dec. 2024 (€120.21 Mil).

Cardiol Therapeutics's annual common stock declined from Dec. 2022 (€102.53 Mil) to Dec. 2023 (€101.52 Mil) but then increased from Dec. 2023 (€101.52 Mil) to Dec. 2024 (€120.21 Mil).


Cardiol Therapeutics Common Stock Historical Data

The historical data trend for Cardiol Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Common Stock Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial 33.32 98.82 102.53 101.52 120.21

Cardiol Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.52 102.69 103.27 102.85 120.21

Cardiol Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Cardiol Therapeutics Business Description

Traded in Other Exchanges
Address
2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics Headlines

No Headlines